Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
XPL Solitario Zinc Corp
DD Dupont De Nemours Inc
RLJ RLJ Lodging Trust
TTEXF Bullion Gold Resources Corp
FRLN Freeline Therapeutics Holdings PLC
PCQ PIMCO California Municipal Income Fund
WULF Terawulf Inc
USB-A US Bancorp
DBTX Decibel Therapeutics Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.

Closing Price
$136.87
Day's Change
3.43 (2.57%)
Bid
--
Ask
--
B/A Size
--
Day's High
136.97
Day's Low
133.50
Volume
(Average)
Volume:
6,661,613

10-day average volume:
6,992,647
6,661,613

Display:

Providers:

UpdateCancel
All providers
Yesterday's News, June 02, 2023
AbbVie Inc. Stock Rises Friday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) rallied 2.57% to $136.87 Friday, on what proved to be an all-around favorable trading session for the stock...(MarketWatch)

June 01, 2023
AbbVie Inc. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) shed 3.28% to $133.44 Thursday, on what proved to be an all-around great trading session for the stock market...(MarketWatch)

May 31, 2023
AbbVie Inc. Stock Outperforms Market On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) rose 1.11% to $137.96 Wednesday, on what proved to be an all-around poor trading session for the stock market...(MarketWatch)

Phase 2 Study of Upadacitinib (RINVOQ(R)) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg])met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than...(PR Newswire)

May 30, 2023
AbbVie Inc. Stock Falls Tuesday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slumped 0.81% to $136.44 Tuesday, on what proved to be an all-around mixed trading session for the stock market...(MarketWatch)

May 26, 2023
AbbVie Inc. Stock Falls Friday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) shed 0.76% to $137.56 Friday, on what proved to be an all-around great trading session for the stock market...(MarketWatch)

May 25, 2023
AbbVie Inc. Stock Falls Thursday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) shed 1.79% to $138.62 Thursday, on what proved to be an all-around mixed trading session for the stock market...(MarketWatch)

May 24, 2023
AbbVie Inc. Stock Falls Wednesday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slid 0.96% to $141.15 Wednesday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ(R) (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress

Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ(R) (upadacitinib) and HUMIRA(R) (adalimumab), both in combination with methotrexate (MTX), are reported for adult patients with moderate to severely active rheumatoid...(PR Newswire)

May 23, 2023
AbbVie Inc. Stock Falls Tuesday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slipped 1.64% to $142.52 Tuesday, on what proved to be an all-around dismal trading session for the stock...(MarketWatch)

May 22, 2023
AbbVie Inc. Stock Falls Monday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slid 0.14% to $144.90 Monday, on what proved to be an all-around mixed trading session for the stock market...(MarketWatch)

May 19, 2023
AbbVie Inc. Stock Rises Friday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) rallied 1.16% to $145.11 Friday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

EPKINLY(TM) (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY(TM) (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or...(BusinessWire)

EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory...(PR Newswire)

May 18, 2023
AbbVie Inc. Stock Rises Thursday, Still Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) inched 0.06% higher to $143.44 Thursday, on what proved to be an all-around favorable trading session for the...(MarketWatch)

U.S. FDA Approves RINVOQ(R) (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults

The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib) at week 12 and week 52 versus placebo1 - Clinical...(PR Newswire)

May 17, 2023
AbbVie Inc. Stock Rises Wednesday, Still Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) inched 0.04% higher to $143.35 Wednesday, on what proved to be an all-around great trading session for the stock...(MarketWatch)

May 16, 2023
AbbVie Inc. Stock Falls Tuesday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slid 2.25% to $143.29 Tuesday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

May 15, 2023
AbbVie Inc. Stock Outperforms Competitors Despite Losses On The Day

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) dropped 0.38% to $146.59 Monday, on what proved to be an all-around great trading session for the stock market...(MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.